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ABSTRACT
Background. Surgical site infections (SSIs) are a common complication following
breast surgery procedures, despite being considered a clean surgery. The prevalence
of SSIs can be minimised with the appropriate use of antibiotic prophylaxis as outlined
in the Australian Therapeutic Guidelines (eTG). The aims of this study were to evaluate
adherence to the eTG for antibiotic prophylaxis in breast surgery procedures at a
Western Australian teaching hospital following an update of the guidelines in 2014 and
examine the impact of prophylactic antibiotics on SSI incidence and length of hospital
stay.
Method. A retrospective cross-sectional study which reviewed medical records from
a random sample of 250 patients selected from 973 patients who underwent breast
surgical procedures between February 2015 and March 2017.
Results. Overall adherence to current eTG occurred in 49.2% (123/250) of operations.
Pre-operative and post-operative antibiotics were prescribed in 98.4% (246/250) and
11.2% (28/250) operations respectively. Adherence rates to three specific elements of
the eTG (drug prescribed, drug dosage and timing of administration) were 91.6%
(229/250), 53.6% (134/250) and 86.4% (216/250) respectively. For the 14.4% (36/250)
patients with relevant drug allergies, there was zero adherence to the eTG. Overall
recorded SSI prevalence was low at 5.2% (13/250). The mean length of stay in patients
(2.3 ± 1.7 days) was not influenced by level of eTG adherence (p= 0.131) or SSIs
(p= 0.306).
Conclusion.These data demonstrate a significant improvement in overall adherence to
the eTG from 13.3% to 49.2% (p=< 0.001). The level of detected SSIs in this study
was low. Further improvement is necessary with respect to prescribing appropriate
antibiotic dosages and for those with allergies.
Subjects Evidence Based Medicine, Infectious Diseases, Internal Medicine, Public Health, Surgery
and Surgical Specialties
Keywords Adherence to guidelines, Antibiotic prophylaxis, Surgical prophylaxis, Breast surgery,
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INTRODUCTION
Surgical site infections (SSIs) are a common complication following breast surgery
procedures, despite being considered a ‘clean surgery’ (Cabaluna et al., 2013; Craft,
Damjanovic & Colwell, 2012). SSIs are also the second most common adverse event in
breast surgical patients with incidences of infection typically ranging from 0.8–26%
(Cabaluna et al., 2013; Craft, Damjanovic & Colwell, 2012; Gulluoglu et al., 2013).
The prevalence of SSIs can be minimized with the appropriate use of pre-operative
antibiotic prophylaxis (Ariyan et al., 2015; Jones, Bunn & Bell-Syer, 2014). This has been
demonstrated in patients undergoing breast surgery (Jaber et al., 2017). A recent study by
Jaber et al. (2017) in 2014 evaluated the appropriateness of surgical antibiotic prophylaxis
for breast surgery procedures and found a statistically significant relationship between
pre-operative prophylactic antibiotic use and successful SSI prevention. The burden of SSIs
not only includes an impact on patient recovery, the associated cost of hospital readmission
and subsequent adjuvant treatment, but also SSI-related patient morbidity and mortality.
Hence the application and adherence to evidence-based guidelines should be considered
to minimize rates of SSIs (Cabaluna et al., 2013; Crawford et al., 2016;Manian, 2014).
In Australia, prescribers are guided by the Australian Antibiotic Therapeutic Guidelines
(eTG) which aim to promote the quality use of medicines by publishing evidence based
standard protocols and up-to-date therapeutic information. In 2014 updates were made
to the eTG and a new section on surgical prophylaxis of breast surgery was included
in the guidelines. According to the current eTG, patients undergoing breast surgery
should receive pre-operative cefazolin 2 grams intravenously (IV) within 60 min, ideally
15 to 30 min before surgical incision. For patients with immediate hypersensitivity to
penicillin, vancomycin 15mg/kg IV, started 30 to 120 min before surgical incision at a
rate 10mg/min is recommended (Antibiotic Expert Groups, 2014). Vancomycin should be
added to cefazolin in suspected patients or patients infected with methicillin-resistant
Staphylococcus aureus (MRSA) (Antibiotic Expert Groups, 2014). Post-operative antibiotics
have not been indicated in these guidelines however the guidelines mention the potential
benefits in obese patients, patients being treated with radiation therapy or in breast
reconstruction patients (Gulluoglu et al., 2013; Manian, 2014; Antibiotic Expert Groups,
2010; Townley et al., 2015; Antibiotic Expert Groups, 2014; Huang et al., 2015; Phillips et al.,
2013; Viola, Raad & Rolston, 2014).
Prior to the update, prescribers would follow the protocol for ‘Head, Neck and Thoracic’
procedures (Antibiotic Expert Groups, 2010). The 2014 study conducted by Jaber et al.,
evaluated prescriber adherence to the eTG in breast surgeries performed at a single
Western Australian teaching hospital prior to the guidelines update in 2014 (Jaber et
al., 2017). Researchers reported low adherence to guidelines (13.3%) and proposed an
improvement would be seen after the update (Jaber et al., 2017). Since that time no study
has been performed to evaluate the effectiveness of these updates nor an improvement in
adherence.
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Aim of the study
The aims of this study were to evaluate adherence to the eTG for antibiotic prophylaxis
in breast surgery procedures at a Western Australian teaching hospital since the 2014
eTG update and to examine the impact of prophylactic antibiotics on SSI incidence and
length of hospital stay.
Ethical approval
The study was approved by the Sir Charles Gairdner Group Human Ethics and Research
Committee (QI:14155) as a quality improvement activity to enhance the safety of medicines
use. Approval of this piece of research included the option to publish the data with a waiver
of individual patient consent. Ethical approval was also granted by the Human Research
Ethics Committee at Curtin University, Perth, Western Australia (HRE2017-0189).
METHODS
This retrospective cross-sectional study was conducted at Sir Charles Gairdner Hospital
(SCGH) in Perth, Western Australia. A total of 973 patients who underwent a breast
surgery procedure between February 2015 and March 2017 at SCGH were identified
by the Pharmacy Department at SCGH using Medicare breast surgery codes by means
of an electronic database. The search involved identifying patients with International
Classification of Disease (ICD-10) codes. C50 was used as well as Australian Medicare
Benefits Schedule principle procedures codes 31,500 to 31,566 which formed a list of
patients not ordered by date, code or medical record number. Patients with missing
important information such as patient treatment, detailed antibiotic use and type of
surgery were excluded. In Australia, Medicare is a Commonwealth government universal
health care system that provides citizens with access to many health services at minimal
cost, including free treatment in public hospitals. The Medicare Benefits Schedule is a
listing of the Medicare services subsidized by the Australian government.
A sample of 250 patients was selected using an online randomiser (Townley et al., 2015;
Social Psychology Network, 2017). This sample size was selected so that the 95% confidence
for the prevalence of guideline adherence would be no wider than ±6%. This degree
of precision was considered adequate for this study. Only the first operation for each
patient was included for analysis. For patients whose files were unavailable, the next patient
sequentially from the random generator list was used.
De-identification of patient and prescriber details was performed during data collection
to ensure confidentiality throughout the study. For this study details gathered from the
medical records were entered into a password protected Microsoft Excel R© Spreadsheet.
Data extracted included patient demographics (age, gender, weight, height and allergies),
the code of the surgeon who performed the procedure, the patients’ ward, the procedure
type, surgery time, any pre-operative or post-operative antibiotics given (drug name,
dose, route of administration, time of administration and frequency of antibiotics given),
adverse drug reactions for both pre- and post-operative antibiotics, signs of infection and
the patient’s length of stay in the hospital.
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Table 1 Patient demographics.
Demographic Gender Mean (± standard deviation)
Female (n= 247) 56.8± 13.7Age
(years) Male (n= 3) 46.7± 22.9
Female (n= 246) 76.1± 20.4Weight
(kg) Male (n= 3) 92.7± 10.8
Female (n= 235) 162.4± 8.0Height
(cm) Male (n= 3) 183± 1.7
In order to calculate adherence to the current version of the eTG, four characteristics
of pre-operative antibiotics recorded for each patient (antibiotic drug, dose, route of
administration and timing of administration) were assessed against the current guidelines,
which recommend the use of cefazolin 2 grams (IV) within 60 min, ideally 15 to 30 min
before surgical incision (Antibiotic Expert Groups, 2014). To be classified as ‘adherent’
the prescriber must have satisfied all of these criteria of the eTG; if not, the treatment was
rendered as ‘non-adherent’. For all other determinations and statistical analysis in this study
the Statistical Package for the Social Science (SPSS) version 23 software was utilised. The
statistical significance of univariate associations between SSIs and adherence, procedure,
prescriber, length of hospital stay (0–2 days vs 3 days or more), and the association between
adherence and length of hospital stay were assessed using the Chi-square test or Fisher’s
Exact test, as appropriate. A Chi-square test was also used to compare levels of adherence
to the eTG before and after the 2014 eTG update. A logistic regression model was used to
identify any multivariate associations with the dependent variables (guideline adherence,
or development of a SSI). Results for the logistic regression are provided as the odds ratio,
its 95% confidence interval (95% CI), and p-value. A p-value <0.05 was taken to indicate
a statistically significant association in all tests.
RESULTS
A total of 250 patients were analysed in this study. Most, 98.8% (247/250), were females
(Table 1). The 14.4% (36/250) of patients who had a documented allergy to either penicillin
or cefalosporins were all female.
There were 25 different types of breast procedures recorded (Table 2). Many
patients underwent multiple procedures in the one operation with an average of 2.1
procedures/operation recorded per patient (median: 2 procedures/patient; range 1–4). A
total of 521 procedures were performed during the 250 operations. The most common
procedures performed were sentinel node biopsy (n= 120; 23.0%) and wide local excision
(n= 88; 16.9%). All male patients received a unilateral mastectomy with one male patient
also receiving a sentinel node biopsy. There was no statistically significant association
between any particular operation and development of a SSI.
There was missing information on specific adherence elements for 10.4% (26/250) of
patients, which related to timing of antibiotic administration. These patients were classified
as non-compliant with respect to timing. Management of 123 patients (49.2%) was found
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Table 2 Types of procedures and association with surgical site infections (SSI). P-values were ob-
tained from Fisher’s Exact test, unless otherwise specified.
Type of procedure Frequency of procedure Frequency (%) of SSI p
Axillary node clearance 52 1 (1.9%) 0.313
Mastectomy (unilateral) 84 4 (4.8%) 1.0
Mastectomy (bilateral) 12 2 (16.7%) 0.123
Sentinel node biopsy 120 5 (4.2%) 0.480*
Wide local excision 88 3 (3.4%) 0.552
Hook wire local excision 68 1 (1.5%) 0.196
Excision 27 2 (7.4%) 0.638
Reconstruction/expanders 6 0 (0.0%) 1.0
Implant insertion 1 0 (0.0%) 1.0
Microdochectomy 6 0 (0.0%) 1.0
Duct excision 5 0 (0.0%) 1.0
Lumpectomy 2 0 (0.0%) 1.0
Seed removal 1 0 (0.0%) 1.0
Soft tissue biopsy 3 1 (33.3%) 0.149
Abscess drainage 5 1 (20.0%) 0.236
Abscess incision 5 1 (20.0%) 0.236
Breast reduction 1 0 (0.0%) 1.0
Hematoma drainage 1 1 (100%) 0.052
DIEP flap breast reconstruction 6 1 (16.7%) 0.277
Wound exploration 2 0 (0.0%) 1.0
Seed localization 2 0 (0.0%) 1.0
Excision biopsy 20 0 (0.0%) 0.608
Re-excision 2 0 (0.0%) 1.0
Lipofilling 1 0 (0.0%) 1.0
Liposuction 1 0 (0.0%) 1.0
Notes.
*p-value obtained from the Chi-square statistic.
to be compliant with the eTG (Table 3). The 95% CI for overall compliance was found to
be: 43.0%–55.4%. Adherence to specific factors of the eTG requirements were: correct drug
91.6% (229/250), correct dose 53.6% (134/250), correct route of administration 97.2%
(243/250) and correct timing of administration 86.4% (216/250) (Table 3). There was zero
adherence to the eTG regarding patient allergies, although the allergies were not recorded
as immediate hypersensitivity reactions to penicillin. Despite 37 patients reported as having
an allergy to penicillin or cefalosporin, 67.6% (25/37) received a cefalosporin (cefalozolin),
29.7% (11/37) received clindamycin, and only one of these patients (2.7%) did not receive
an antibiotic.
Adherence to the eTG was found to be significantly improved since the study by Jaber
et al. reported 13.3% compliance (p< 0.001, Chi-square test). In the current study, 5.2%
(13/250) of patients developed a reported SSI after surgery. No statistically significant
relationship was found between adherence to the eTG and SSIs (OR ratio: 1.36; 95%
CI [0.43–4.30]; p = 0.597). Of the patients who had received appropriate pre-operative
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Table 3 Levels of adherence to specific elements of the Australian Antibiotic Therapeutic Guidelines
in 250 operations (blue colour indicates element complied with; blank colour indicates element not
complied with).
Correct adherence to prescribing parameters
when compared to the
Therapeutic Guidelines: Antibiotic Version 15
Number of operations
Antibiotic selection Route Dose Timing (n= 250)(%)
123 49.2
79 31.6
11 4.4
13 5.2
2 0.8
1 0.4
12 4.8
5 2.0
1 0.4
3 1.2
antibiotic treatment, 6.5% (8/123) developed a reported SSI, while 4.9% (5/103) of the
patients who did not receive appropriate treatment developed an SSI.
On average patients stayed at the hospital for a mean (±standard deviation) of 2.3
±1.7 days (median: 2 days; range 1–16 days). With this length of stay divided into short
(0–2 days) vs longer (3 or more days), no significant association was found between level
of adherence and length of stay (OR: 2.0; 95% CI [0.5–7.6]; p= 0.3144) nor SSI occurrence
(p = 0.596). A significant relationship was found between using cefazolin and a decreased
length of stay (p= 0.037), with 87.8% (201/229) of those who were given cefazolin staying
1-2 days, compared to 71.4% (15/21) of those who were not taking cefazolin. There were
4.6% (10/216) patients with a length of stay less than three days who developed a SSI, whilst
8.8% (3/34) of those who stayed longer than two days developed a SSI.
A total of seven surgeons were recorded in this study. There was no statistically significant
relationship found between prescribers and level of adherence (p = 0.631) with prescriber
adherence to the eTG ranging from 25 to 100%. Similarly, between prescribers and
developing an SSI (p = 0.748) with individual SSIs rates for prescribers ranging from
0-14.3%. No significance was found between prescribers and whether they gave pre-
operative antibiotics with the rates of pre-operative antibiotic given to patients for each
prescriber ranging between 90.7% and 100%. A statistically significant association was seen
between prescribers and whether post-operative antibiotics were given (p<0.05) with 11.2%
(28/250) in patients having received post-operative antibiotics despite not being specified
by the eTG. A majority of patients who received post-operative antibiotics (57.1%; 16/28)
were prescribed cefalexin, however other antibiotics including clindamycin (14.3%; 4/28),
dicloxacillin (10.7%; 3/28), cefazolin (3.6%; 1/28), flucloxacillin (3.6%; 1/28), amoxicillin
(7.1%; 2/28) amoxicillin with clavulanic acid (3.6%; 1/28) were also prescribed.
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DISCUSSION
This is the first study conducted since the introduction of the new eTG in 2014. The
adherence level of 49.2% (123 operations) was higher (p < 0.001) than the 13.3% (20
operations) reported by Jaber et al. (2017) and zero adherence by Habak et al. (2013)
who investigated adherence to the previous version of the eTG. This is an improved
result compared to the previous study yet still not reflective of strict adherence to the
breast surgical antibiotic prophylaxis eTG guidelines. The main factor that contributed to
non-adherence, was antibiotic dosage which accounted for 46.4% of operations. This was
different to the study conducted by Jaber et al. (2017) where inappropriate timing of the
antibiotic was the dominant factor contributing to non-adherence. To ensure adherence
to guidelines, there are measures that can be implemented as suggested by Nabor, Buckley
& Lapitan (2015). These measures include medical education presentations and laminated
summaries of guidelines posted in surgical areas such as operating rooms (Nabor, Buckley
& Lapitan, 2015).
Antibiotic prophylaxis was used in 98.4% of patients who underwent a breast procedure
which was higher than the 92.7% and 53% reported by Jaber et al. (2017) and Habak et al.
(2013) respectively. Jaber et al. investigated the use of prophylactic antibiotics in 150 breast
operations in 150 patients whilst Habak et al. investigated prophylactic antibiotic use in
134 breast operations in 95 patients. Both studies were carried out in Western Australian
hospitals (Jaber et al., 2017;Habak et al., 2013). This shows an increased use of prophylactic
antibiotics in the last two evaluations.
This study related to the oncological management of breast surgery as part of treatment.
Despite the inclusion of one patient who had breast reduction and one patient who had
implant insertion, these surgeries were related to an original life-saving procedure rather
than a cosmetic procedure, as these are not performed at the study hospital. Antibiotics
play an important role in these types of procedures as reported by Khan (2010).
Of the 250 patients analysed in this study, 37 patients were recorded with an allergy to
penicillin or cephalosporin, although there was no evidence that these were associated with
immediate hypersensitivity reactions. It was found that none of the prescribers adhered
to the eTG and had prescribed either cefazolin or clindamycin instead of vancomycin
as stipulated in the eTG. Vancomycin or clindamycin are second-line choices for SSI
prophylaxis in cases where cefalosporin antibiotics were contraindicated (Baghaki, Soybir
& Soran, 2014). Possible reasons for reluctance by clinician to prescribe vancomycin
include adverse effects such as red man syndrome which may limit its use for some
surgeons. Furthermore, vancomycin is contraindicated in patients with renal impairment
(Bratzler et al., 2013).
No relationship was found between adherence to therapeutic guidelines and SSIs (p =
0.596). A recent study by Yang et al. also reported that there was no significant difference
between SSIs and cefazolin administration in patients who underwent breast procedures
such as a mastectomy, whereas development of SSIs with and without prophylactic
pre-operative antibiotics was 7.2% and 4.2% respectively (Yang et al., 2017). In their paper
they suggested that to decrease the development of post-operative SSIs other factors such
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as hypertension, diabetes, and advanced age should be taken into consideration (Yang et
al., 2017).
While no significant association was found between the different operations and
occurrence of a SSI, hematoma drainage has been clinically shown to impart an increased
rate of SSIs for patients especially with a longer drain duration (Eroglu et al., 2014). The
study was able to collect data only on SSIs that were treated at the hospital. Other patients
may have developed an SSI but were treated by a general practitioner or at another hospital.
There is a lack of consensus in current practice for the use of pre-operative antibiotic
prophylaxis and this is largely attributed to the lack of trial evidence in preventing SSIs in
general patients after breast surgery (Ng et al., 2007). Also, the variation in guidelines and
adherence can be attributed to changing patient risk factors. For instance, in a study by
Eroglu et al. (2014) researchers reported that prescribers were more inclined to prescribe
antibiotics prophylactically in patients with risk factors which included older age, diabetes
mellitus, immunodeficiency and those who underwent pre-operative chemotherapy or
radiotherapy prior to breast surgical procedures. Other risk factors that may contribute
to post-operative infections in breast surgery include length of surgery, type of surgery,
smoking, steroid use, seroma, hematoma, surgical drain, second drain placed, prolonged
close suction drainage and immediate breast reconstruction (Vilar-Compte et al., 2004;
Throckmorton et al., 2009; Tejirian, DiFronzo & Haigh, 2006; Penel et al., 2007; De Blacam
et al., 2012; Vilar-Compte et al., 2009; Gao et al., 2010; Olsen et al., 2008; Xue et al., 2012).
When risk factors are present in patients undergoing breast surgery, the administration of
prophylactic antibiotics should be taken into account. This is supported by a recent study
by Vieira et al. (2016) which reported that SSIs were significantly more common in the
control group that did not receive antibiotic prophylaxis despite having risk factors.
For patients that are not at risk for SSIs after breast surgery, routine antibiotic prophylaxis
is not necessary (Gulluoglu et al., 2013; Vilar-Compte et al., 2004; Tejirian, DiFronzo &
Haigh, 2006; Olsen et al., 2008). According to Xue et al. (2012) antibiotic prophylaxis is not
an independent protective factor in SSI development and systematic administration for
breast surgery is not necessary for general patients but may be considered if other risk
factors were present.
In this present study no statistical significance was found between prescribers and
adherence to the eTG (p= 0.631). As mentioned previously there is a lack of clinical studies
which support the use of antibiotic prophylaxis which may have influenced prescribers in
the present study. The lack of consensus of antibiotic prophylaxis has also been reported
by breast surgeons in the United Kingdom, following nationwide surveys. (Ng et al., 2007)
The eTG does not indicate that antibiotic prophylaxis is discretionary (Antibiotic Expert
Groups, 2014).
Where patients were prescribed post-operative antibiotics, these did not adhere
to the eTG in this study. Post-operative prophylaxis should not exceed 24 h and
should be considered on an individual patient basis. (Antibiotic Expert Groups, 2014)
Similar results have been reported by Jaber et al. (2017) and Habak et al. (2013).
According to other studies to prevent SSIs after breast and/or axillary surgery some
surgeons prefer post-operative prophylaxis for patients with drains. In patients
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receiving a surgical drain, mastectomy, immediate reconstruction or receiving prior
radiation therapy or chemotherapy, pre- and post-operative prophylactic antibiotics are
used (Vilar-Compte et al., 2004; Throckmorton et al., 2009; Tejirian, DiFronzo & Haigh,
2006; De Blacam et al., 2012; Olsen et al., 2008). Phillips et al. (2013), Manian (2014)
Viola, Raad & Rolston (2014), and Elbur et al. (2013) each have emphasised the increased
risk of antibiotic resistance and drug-related complications such as Clostridium difficile
when post-operative antibiotic prophylaxis was used after breast surgeries, due to the lack
of evidence.
It was also found that the mean length of stay was not influenced by the level of eTG
adherence. However, the length of stay and SSIs were reduced when cefazolin was given.
This somewhat supported the study conducted by Toor et al. (2015) who found that the
administration of prophylactic antibiotics not only led to reduced SSIs but also led to a
shortened hospital stay.
The strength of this study was a larger sample size (n= 250) compared to the previous
study conducted by Jaber et al. which used a sample size (n= 150). The results should be
generalisable to this hospital but may not reflect practice elsewhere.
Limitations of this study included the sample size (n= 250) which restricted the ability
to identify large numbers of SSIs. Patients might seek treatment for SSIs from their
general practitioners or other hospitals without returning to SCGH which may raise
the incidence of SSIs recorded within this study cohort. A further limitation was that
detailed examination of SSIs and the causative factors such as pathogens, appropriate
hand washing and other procedures, were beyond the scope of this study. Also, missing
information within 26 patient medical files regarding adherence, specifically the timing of
antibiotic administration meant these patients were excluded from the overall compliance
assessment.
CONCLUSIONS
There was a significant improvement in adherence to surgical antibiotic prophylaxis
guidelines in breast surgery from 13.3% to 49.2% compared to a similar study conducted
by Jaber et al. (2017). Further improvement is necessary especially with respect to recording
of antibiotic timing of administration, adherence to guidelines for antibiotic dosage and also
when allergy is reported to the primary recommended antibiotic, that the recommended
alternative antibiotic is selected. From the available evidence, incidence of SSIs identified
in the study was low and there was no relationship with adherence to guidelines, indicating
that the prophylaxis followed was reasonably effective.
ACKNOWLEDGEMENTS
The authors acknowledge the assistance of the medical records department of the research
hospital for their support and assistance.
Lavers et al. (2018), PeerJ, DOI 10.7717/peerj.5724 9/13
ADDITIONAL INFORMATION AND DECLARATIONS
Funding
The authors received no funding for this work.
Competing Interests
The authors declare there are no competing interests.
Author Contributions
• Ainslie Lavers andWai Siong Yip performed the experiments, analyzed the data, prepared
figures and/or tables, authored or reviewed drafts of the paper, approved the final draft.
• Bruce Sunderland and Richard Parsons conceived and designed the experiments,
analyzed the data, contributed reagents/materials/analysis tools, authored or reviewed
drafts of the paper, approved the final draft.
• Sarah Mackenzie and Jason Seet conceived and designed the experiments, analyzed the
data, authored or reviewed drafts of the paper, approved the final draft, provided access
to hospital medical records.
• Petra Czarniak conceived and designed the experiments, analyzed the data, contributed
reagents/materials/analysis tools, prepared figures and/or tables, authored or reviewed
drafts of the paper, approved the final draft.
Human Ethics
The following information was supplied relating to ethical approvals (i.e., approving body
and any reference numbers):
The study was conducted at Sir Charles Gairdner Hospital (SCGH) in Perth, Western
Australia and approved by the Sir Charles Gairdner Group Human Ethics and Research
Committee (QI:14155) as a quality improvement activity to enhance the safety of medicines
use. Ethical approval was also granted by the Human Research Ethics Committee at Curtin
University, Perth, Western Australia (HRE2017-0189).
Data Availability
The following information was supplied regarding data availability:
Czarniak, Petra; Sunderland, Bruce; Parsons, Richard; Lavers, Ainslie; Yip, Wai Siong;
Mackenzie, Sarah; Seet, Jason (2018): Data on surgical antibiotic prophylaxis use and
infection prevalence in breast surgery procedures at a tertiary hospital inWestern Australia.
Curtin University. http://dx.doi.org/10.4225/06/5aaf1279876c8
REFERENCES
Antibiotic Expert Groups. 2010. Therapeutic guidelines: antibiotic. Version 14. Mel-
bourne: Therapeutic Guidelines Limited.
Antibiotic Expert Groups. 2014. Therapeutic guidelines: antibiotic. Version 15. Mel-
bourne: Therapeutic Guidelines Limited.
Lavers et al. (2018), PeerJ, DOI 10.7717/peerj.5724 10/13
Ariyan S, Martin J, Lal A, Cheng D, Borah GL, Chung KC, Conly J, Havlik R, LeeW,
McGrathMH, Pribaz J, Young VL. 2015. Antibiotic prophylaxis for preventing
surgical-site infection in plastic surgery: an evidence-based consensus conference
statement from the American Association of Plastic Surgeons. Plastic and Reconstruc-
tive Surgery 135(6):1723–1739 DOI 10.1097/PRS.0000000000001265.
Baghaki S, Soybir GR, Soran A. 2014. Guideline for antimicrobial prophylaxis in breast
surgery. Journal of Breast Health 10(2):79–82 DOI 10.5152/tjbh.2014.1959.
Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, BolonMK, Fish
DN, Napolitano LM, Sawyer RG, Slain JP, Weinstein RA. 2013. Clinical practice
guidelines for antimicrobial prophylaxis in surgery. American Journal of Health-
System Pharmacy 70(3):195–283 DOI 10.2146/ajhp120568.
Cabaluna ND, Uy GB, Galicia RM, Cortez SC, YrayMD, Buckley BS. 2013. A ran-
domized, double-blinded placebo-controlled clinical trial of the routine use of pre-
operative antibiotic prophylaxis in modified radical mastectomy.World Journal of
Surgery 37(1):59–66 DOI 10.1007/s00268-012-1816-5.
Craft RO, Damjanovic B, Colwell AS. 2012. Evidence-based protocol for infection
control in immediate implant-based breast reconstruction. Annals of Plastic Surgery
69(4):446–450 DOI 10.1097/SAP.0b013e31824a215a.
Crawford CB, Clay JA, Seydel AS,Wernberg JA. 2016. Surgical site infections
in breast surgery: the use of pre-operative antibiotics for elective, nonrecon-
structive procedures. International Journal of Breast Cancer 2016:1645192
DOI 10.1155/2016/1645192.
De Blacam C, Ogunleye AA, Momoh AO, Colakoglu S, Tobias AM, Sharma R, Houli-
hanMJ, Lee BT. 2012.High body mass index and smoking predict morbidity in
breast cancer surgery: a multivariate analysis of 26,988 patients from the national
surgical quality improvement program database. Annals of Surgery 255(3):551–555
DOI 10.1097/SLA.0b013e318246c294.
Elbur AI, Yousif MA, Elsayed AS, Abdel-RahmanME. 2013. An audit of prophylactic
surgical antibiotic use in a sudanese teaching hospital. International Journal of
Clinical Pharmacy 35(1):149–153 DOI 10.1007/s11096-012-9719-y.
Eroglu A, Karasoy D, Kurt H, Baskan S. 2014. National practice in antibiotic prophylaxis
in breast cancer surgery. Journal of Clinical Medicine Research 6(1):30–35.
Gao YX, Xu L, Ye JM,Wang DM, Zhao JX, Zhang LB, Duan XN, Liu YH. 2010. Analysis
of risk factors of surgical site infections in breast cancer. Chinese Medical Journal
123(5):559–562.
Gulluoglu BM, Guler SA, UgurluMU, Culha G. 2013. Efficacy of prophylactic antibiotic
administration for breast cancer surgery in overweight or obese patients: a random-
ized controlled trial. Annals of Surgery 257(1):37–43
DOI 10.1097/SLA.0b013e31826d832d.
Habak JE, Varma S, Kiani M, Twaddle A, Emmerton LM. 2013. Prophylactic antibiotic
use in breast cancer surgery patients. Journal of Pharmacy Practice and Research
43(2):101–104 DOI 10.1002/j.2055-2335.2013.tb00229.x.
Lavers et al. (2018), PeerJ, DOI 10.7717/peerj.5724 11/13
Huang N, LiuM, Yu P,Wu J. 2015. Antibiotic prophylaxis in prosthesis-based
mammoplasty: a systematic review. International Journal of Surgery 15:31–37
DOI 10.1016/j.ijsu.2015.01.020.
Jaber S, Rogers C, Sunderland B, Parsons R, MacKenzie S, Seet J, Czarniak P. 2017.
Appropriateness of surgical antibiotic prophylaxis for breast surgery procedures.
International Journal of Clinical Pharmacy 39(2):483–486
DOI 10.1007/s11096-017-0434-6.
Jones DJ, Bunn F, Bell-Syer SV. 2014. Prophylactic antibiotics to prevent surgical site
infection after breast cancer surgery. Cochrane Database of Systematic Reviews 9(3).
Khan UD. 2010. Breast augmentation, antibiotic prophylaxis and infection: comparative
analysis of 1628 primary augmentation mammoplasties to assess the role and
efficacy of length of antibiotic prophylaxis. Aesthetic Plastic Surgery 34(1):42–47
DOI 10.1007/s00266-009-9427-8.
Manian FA. 2014. The role of post-operative factors in surgical site infections: time to
take notice. Clinical Infectious Diseases 59(9):1272–1276 DOI 10.1093/cid/ciu552.
NaborMIP, Buckley BS, LapitanMCM. 2015. Compliance with international guidelines
on antibiotic prophylaxis for elective surgeries at a tertiary-level hospital in the
Philippines. Healthcare Infection 20(3–4):145–151 DOI 10.1071/HI15018.
NgD, Trivedi PM, Sharma AK, Banerjee D. 2007. Current use of antibiotic pro-
phylaxis in breast surgery: a nationwide survey. The Breast 16(1):68–72
DOI 10.1016/j.breast.2006.06.004.
OlsenMA, Lefta M, Dietz JR, Brandt KE, Aft R, Matthews R, Mayfield J, Fraser VJ.
2008. Risk factors for surgical site infection after major breast operation. Journal of
the American College of Surgeons 207(3):326–335
DOI 10.1016/j.jamcollsurg.2008.04.021.
Penel N, Yazdanpanah Y, Chauvet MP, Clisant S, Giard S, Neu JC, Lefebvre D, Fournier
C, Bonneterre J. 2007. Prevention of surgical site infection after breast cancer
surgery by targeted prophylaxis antibiotic in patients at high risk of surgical site
infection. Journal of Surgical Oncology 96(2):124–129 DOI 10.1002/jso.20796.
Phillips BT, Bishawi M, DagumAB, Khan SU, Bui DT. 2013. A systematic review of
antibiotic use and infection in breast reconstruction: what is the evidence? Plastic and
Reconstructive Surgery 131(1):1–13 DOI 10.1097/PRS.0b013e3182729c39.
Social Psychology Network. 2017. Research Randomizer: random sample and random
assignment made easy. Middletown: Social Psychology Network. Available at https:
//www.randomizer.org/ (accessed on 30 September 2017).
Tejirian T, DiFronzo LA, Haigh PI. 2006. Antibiotic prophylaxis for preventing wound
infection after breast surgery: a systematic review and meta-analysis. Journal of the
American College of Surgeons 203(5):729–734 DOI 10.1016/j.jamcollsurg.2006.07.013.
Throckmorton AD, Boughey JC, Boostrom SY, Holifield AC, Stobbs MM, Hoskin
T, Baddour LM, Degnim AC. 2009. Post-operative prophylactic antibiotics and
surgical site infection rates in breast surgery patients. Annals of Surgical Oncology
16(9):2464–2469 DOI 10.1245/s10434-009-0542-1.
Lavers et al. (2018), PeerJ, DOI 10.7717/peerj.5724 12/13
Toor AA, FarookaMW, AyyazM, Sarwar H, Malik AA, Shabbir F. 2015. Pre-operative
antibiotic use reduces surgical site infection. Journal of Pakistan Medical Association
65(7):733–736.
TownleyWA, Baluch N, Bagher S, Maass SW, O’Neill A, Zhong T, Hofer SO. 2015. A
single pre-operative antibiotic dose is as effective as continued antibiotic prophylaxis
in implant-based breast reconstruction: a matched cohort study. Journal of Plastic,
Reconstructive & Aesthetic Surgery 68(5):673–678 DOI 10.1016/j.bjps.2014.12.041.
Vieira LF, DeMelo Neto AF, SchioMR, De Oliveira JA, Almeida CL, Ferraz DM.
2016. Controversies in reduction mammoplasty: being a ‘‘clean’’ operation,
does it mandate antibiotic prophylaxis? Surgical Infections 17(5):596–600
DOI 10.1089/sur.2016.072.
Vilar-Compte CD, Jacquemin B, Robles-Vidal C, Volkow P. 2004. Surgical site infec-
tions in breast surgery: case-control study.World Journal of Surgery 28(3):242–246
DOI 10.1007/s00268-003-7193-3.
Vilar-Compte D, Rosales S, Hernandez-Mello N, Maafs E, Volkow P. 2009. Surveil-
lance, control, and prevention of surgical site infections in breast cancer surgery:
a 5-year experience. American Journal of Infection Control 37(8):674–679
DOI 10.1016/j.ajic.2009.02.010.
Viola GM, Raad II, Rolston KV. 2014. Breast tissue expander-related infections:
perioperative antimicrobial regimens. Infection Control and Hospital Epidemiology
35(1):75–81 DOI 10.1086/674390.
Xue DQ, Qian C, Yang L,Wang XF. 2012. Risk factors for surgical site infections after
breast surgery: a systematic review and meta-analysis. European Journal of Surgical
Oncology 38(5):375–381 DOI 10.1016/j.ejso.2012.02.179.
Yang S, Liu G, Tang D, Cai D. 2017. Evaluation intravenous drip cefazolin prophylaxis
of breast cancer surgery site infection. Journal of Craniofacial Surgery 28(6):527–531
DOI 10.1097/SCS.0000000000003780.
Lavers et al. (2018), PeerJ, DOI 10.7717/peerj.5724 13/13
